Effect of udenafil on vascular smooth muscle cell proliferation and neointimal hyperplasia in rat carotid artery injury model

Korean Circulation Journal

Volumn 38, Issue 6, 2008, Pages 320-324

  Jun, Ho Joe ^a   Kwang, Suk Lim ^a   Ji, Yong Jin ^a   Kyung, Soo Kim ^a  

^a Hanyang University College of Medicine   (South Korea)

Author keywords

Neointimal hyperplasia; Smooth muscle cell; Udenafil

Indexed keywords

UDENAFIL;

ADVENTITIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL DIAMETER; CAROTID ARTERY DISEASE; CAROTID ARTERY INJURY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG INHIBITION; DRUG MECHANISM; IMAGE ANALYSIS; INTIMA; MORPHOLOGY; NONHUMAN; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

EID: 48349100265     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2008.38.6.320     Document Type: Article

References (26)

1. Popma JJ, Califf RM, Topol EJ. Clinical trials of restenosis after coronary angioplasty. Circulation 1991; 84: 1426-36.
2. Tahk SJ. Strategies for the prevention and treatment of intracoronary stent restenosis. Korean Circ J 1997; 27: 251-64.
3. Clowes AW, Clowes MM. Kinetics of cellular proliferation after arterial injury: II. inhibition of smooth muscle growth by heparin. Lab Invest 1985; 52: 611-6.
4. Park SJ, Kim HS, Yang HM, et al. Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. Korean Circ J 2004; 34: 346-55.
5. Tanaka H, Sukhova G, Schwartz D, Libby P. Proliferating arterial smooth muscle cells after balloon injury express TNF-alpha but interleukin-1 or basic fibroblastic growth factor. Arteroscler Thromb Vasc Biol 1996; 16: 12-8.
6. Clausell N, de Lima VC, Molossi S, et al. Expression of tumor necrosis factor alpha and accumulation of fibronectin in coronary artery restenotic lesions retrieved by atherectomy. Br Heart J 1995; 73: 534-9.
7. Linder V, Reidy MA. Expression of basic fibroblast growth factor and its receptor by smooth muscle cells and endothelium in injured rat arteries. Circ Res 1993; 73: 589-95.
8. Baek SH, March KL. Gene therapy for restenosis: getting nearer the heart of the matter. Circ Res 1998; 82: 295-305.
9. Cho MC, Kwak NJ, Piao H, et al. Effect of paclitaxel local delivery on neointimal formation after endothelial denudation of the rat carotid artery. Korean Circ J 2000; 30: 198-207.
10. Califf RM, Fortin DF, Frid DJ, et al. Restenosis after coronary angioplasty: an overview. J Am Coll Cardiol 1991; 17 (6 Suppl B): 2B-13B.
11. Seung KB. Drug eluting stent and percutaneous coronary intervention. Korean Circ J 2003; 33: 857-60.
12. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-23.
13. Stone GW, Ellis SG Cox DA, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent. Circulation 2004; 109: 1942-7.
14. Kalsi JS, Ralph DJ, Thomas P, et al. A nitric oxide-releasing PDE5 inhibitor relaxes human corpus cavernosum in the absence of endogenous nitric oxide. J Sex Med 2005; 2: 53-7.
15. Tantini B, Manes A, Fiumana E, et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131-8.
16. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989; 83: 1774-7.
17. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Repair Crit Care Med 2005; 172: 105-13.
18. Fukumoto S, Koyama H, Hosoi M, et al. Distinct role of cAMP and cGMP in the cell cycle control of vascular smooth muscle cells. Circ Res 1999; 85: 985-91.
19. Chiche JD, Schlutsmeyer SM, Bloch DB, et al. Adenovirus-mediated gene transfer of cGMP-dependent protein kinase increases the sensitivity of cultured vascular smooth muscle cells to the anti-proliferative and pro-apoptotic effects of nitric oxide/cGMP. J Biol Chem 1998; 273: 34263-71.
20. Lincoln TM, Cornwell TL. Intracellular cyclic GMP receptor proteins. FASEB J 1993; 7: 328-38.
21. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990; 87: 5193-7.
22. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996; 78: 225-30.
23. Mattsson EJ, Kohler TR, Vergel SM, Clowes AW. Increased blood flow induces regression of intimai hyperplasia. Arterioscler Thromb Vasc Biol 1997; 17: 2245-9.
24. Liu MW, Anderson PG, Luo JF, Roubin GS. Local delivery of ethanol inhibits intimal hyperplasia in pig coronary arteries after balloon injury. Circulation 1997; 96: 2295-301.
25. Kwon JS, Park SS, Kim YG, et al. Perivascular delivery of paclitaxel with F-127 pluronic gel inhibits neointimal hyperplasia in a rat carotid artery injury model. Korean Circ J 2005; 35: 221-7.
26. Kim DW, Kwon JS, Kim YG, et al. Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model. Circulation 2004; 109: 1558-63.